Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes

Patent No. EP3152234 (titled "Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes") was filed by Cellvax on Jun 5, 2015. The application was issued on Jun 26, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HOFFMANN EITLEApr 8, 2021HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3152234

CELLVAX
Application Number
EP15732846A
Filing Date
Jun 5, 2015
Status
Patent Maintained As Amended
May 24, 2024
Publication Date
Jun 26, 2024